Erythropoietin and hepatitis C therapy: Useful adjuvant therapy but remember to treat the patient and not just a number

Canadian Journal of Gastroenterology

Volumn 20, Issue 8, 2006, Pages 519-520

  Yoshida, Eric M ^a,c   Santos, Anne Dar ^a   Partovi, Nilufar ^a   Ford, Jo Ann E ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b The BC Hepatitis Program   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ERYTHROPOIETIN; HEMOGLOBIN; PEGASYS RBV; PEGETRON; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ADJUVANT THERAPY; ANEMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERANCE; EDITORIAL; ERYTHROCYTE APLASIA; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33749340688     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/793589     Document Type: Editorial

References (14)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
4. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006;23:397-408.
5. Sherman M, Cohen L, Cooper MA, et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-485.
6. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001;37(1 Suppl 1):S182-238. (Erratum in 2001;38:442)
7. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19 Suppl 1:17-24.
8. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000;31:997-1004
9. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Inf Dis 2003;37 Suppl 4:S315-22.
10. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
11. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
12. Afdhal NH, Dieterich DT, Pockros PJ, et al; Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
13. Fung S, Kaita K, Wong F. Effect of erythropoietin-alpha on sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Can J Gastroenterol 2006;20:199 (Abst).
14. Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005;100:1415-19.